Ellen Welch

Affiliations: 
 
Google:
"Ellen Welch"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Luban J, Sattler R, Mühlberger E, et al. (2020) The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines. Virus Research. 198246
Feng Z, Ling KKY, Zhao X, et al. (2020) Corrigendum to: Pharmacologically-induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset. Human Molecular Genetics
Luban J, Sattler R, Mühlberger E, et al. (2020) The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines. Biorxiv : the Preprint Server For Biology
Friesen WJ, Johnson B, Sierra J, et al. (2018) The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential. Plos One. 13: e0206158
Friesen WJ, Trotta CR, Tomizawa Y, et al. (2017) The nucleoside analog clitocine is a potent and efficacious readthrough agent. Rna (New York, N.Y.)
Roy B, Friesen WJ, Tomizawa Y, et al. (2016) Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. Proceedings of the National Academy of Sciences of the United States of America
Woll MG, Qi H, Turpoff A, et al. (2016) Discovery and optimization of small molecule splicing modifiers of survival motor neuron 2 (SMN2) as a treatment for spinal muscular atrophy. Journal of Medicinal Chemistry
Feng Z, Ling KK, Zhao X, et al. (2016) Pharmacologically-induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset. Human Molecular Genetics
Naryshkin NA, Weetall M, Dakka A, et al. (2014) Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science (New York, N.Y.). 345: 688-93
Kerem E, Konstan MW, De Boeck K, et al. (2014) Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine. 2: 539-47
See more...